ADVFN ADVFN

Hot Features

Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
125,74
-0,60
( -0,47% )
Mis à jour : 20:37:28

Gilead Sciences Inc (GILD) Action

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Statistiques et détails clés

Dernier
125,74
( -0,47% )
Prix Achat
125,73
Prix Vente
125,75
Volume échangé
2 880 883
125,50 Fourchette du Jour 127,62
107,75 Plage de 52 semaines 157,29
Cap du marché
Clôture Veille
126,34
Ouverture
127,275
Dernière Transaction
39
@
125.7279
Dernière heure de transaction
20:37:33
Volume financier
US$ 363 752 877
VWAP
126,2644
Volume moyen (3 m)
US$ 7 106 255
Actions en circulation
1 241 569 874
Rendement du Dividende (LTM)
3,19 (2,50%)
Ratio Cours sur Bénéfices
17,39
Bénéfice par action (BPA)
7,35
Chiffre d'affairess (LTM)
29,74B
Bénéfice net (LTM)
9,22B

À propos de Gilead Sciences Inc

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV... Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California. Show more

Secteur
Healthcare
Industrie
Pharmaceuticals
Site Web
Siège social
Foster City, United States
Fondé
1987
Gilead Sciences Inc est coté dans le secteur Healthcare de la NASDAQ avec le ticker GILD. Le dernier cours de clôture d'Gilead Sciences était de US$126,34. Au cours de la dernière année, les actions de Gilead Sciences ont été négociées dans une fourchette de prix de US$ 107,75 à US$ 157,29.

Gilead Sciences compte actuellement 1 241 569 874 actions en circulation. La capitalisation boursière d'Gilead Sciences est de US$156,11 milliard. Gilead Sciences a un ratio cours/bénéfice (ratio PE) de 17.39.

Flux d'options Gilead Sciences (GILD)

Flux global

Haussier

Prime nette

591k

Calls / Puts

14,29%

Ach. / Vent.

166,67%

OTM / ITM

100,00%

Sweeps Ratio

0,00%

GILD Dernières nouvelles

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.180.143357757248125.56128.86123.679775075126.41625263CS
4-1.85-1.44995689317127.59131.66121.399548262126.24751619CS
12-14.365-10.2530245173140.105142.97121.397244326130.34075207CS
263.282.67842560836122.46157.29116.887017778135.40070304CS
5214.2712.8016506683111.47157.29107.756803314126.63837775CS
15649.48564.894105304676.255157.2962.07708417299.05081674CS
26056.9982.894545454568.75157.2957.165719991287.22956741CS

GILD - Frequently Asked Questions (FAQ)

What is the current Gilead Sciences Inc share price?
The current share price of Gilead Sciences Inc is US$ 125,74
How many Gilead Sciences Inc shares are in issue?
Gilead Sciences Inc has 1 241 569 874 shares in issue
What is the market cap of Gilead Sciences Inc?
The market capitalisation of Gilead Sciences Inc is USD 156,11B
What is the 1 year trading range for Gilead Sciences Inc share price?
Gilead Sciences Inc has traded in the range of US$ 107,75 to US$ 157,29 during the past year
What is the PE ratio of Gilead Sciences Inc?
The price to earnings ratio of Gilead Sciences Inc is 17,39
What is the cash to sales ratio of Gilead Sciences Inc?
The cash to sales ratio of Gilead Sciences Inc is 5,34
What is the registered address of Gilead Sciences Inc?
The registered address for Gilead Sciences Inc is 333 Lakeside Drive, Foster City, California, 94404
What is the Gilead Sciences Inc website address?
The website address for Gilead Sciences Inc is www.gilead.com
Which industry sector does Gilead Sciences Inc operate in?
Gilead Sciences Inc operates in the Pharmaceuticals sector

GILD Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock